Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: Initially, 10 mg once daily. Usual maintenance: 20-40 mg daily as a single dose or in 2 divided doses. Max: 80 mg daily. In combination with diuretics: Initially, 5 mg once daily.
Child: ≥6 years Initially, 0.2 mg/kg (up to 10 mg) once daily, may titrate up to 0.6 mg/kg once daily as needed. Max: 40 mg daily.
Suy thận
CrCl (mL/min) Dosage
Initially, 5 mg once daily, may be titrated until blood pressure is controlled. Max: 40 mg daily.

Cách dùng
May be taken with or without food.
Chống chỉ định
History of angioedema with or without previous ACE inhibitor therapy. Pregnancy. Concomitant use with aliskiren in patients with diabetes and renal impairment (GFR <60 mL/min/1.73 m2); concurrent use with or within 36 hours of switching to or from a neprilysin inhibitor (e.g. sacubitril).
Thận trọng
Patient with CHF, ischaemic heart disease, severe aortic stenosis, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction, cerebrovascular disease, hyponatraemia, volume and/or salt depletion, unilateral or bilateral renal artery stenosis, diabetes mellitus, ascites, collagen vascular disease. Patient undergoing major surgery, dialysis, apheresis, or desensitisation treatment (e.g. hymenoptera venom). Black patient. Renal and hepatic impairment. Children and elderly. Lactation.
Tác dụng không mong muốn
Significant: Symptomatic hypotension with or without syncope; reduced renal function (including acute renal failure), hyperkalaemia, non-productive cough.
Blood and lymphatic system disorders: Haemolytic anaemia, thrombocytopenia, eosinophilia.
Gastrointestinal disorders: Nausea, vomiting, constipation, gastritis, melaena.
General disorders and administration site conditions: Fatigue, asthenia.
Investigations: Increased uric acid, blood glucose, serum bilirubin, and liver enzymes; ECG changes.
Metabolism and nutrition disorders: Hyponatraemia, proteinuria.
Musculoskeletal and connective tissue disorders: Hypertonia, myalgia, arthralgia, arthritis.
Nervous system disorders: Dizziness, headache, somnolence, paraesthesia.
Psychiatric disorders: Insomnia, nervousness, anxiety.
Renal and urinary disorders: UTI, urinary frequency.
Reproductive system and breast disorders: Decreased libido, impotence.
Respiratory, thoracic and mediastinal disorders: Bronchitis, asthma, dyspnoea, sinusitis.
Skin and subcutaneous tissue disorders: Alopecia, Stevens-Johnson syndrome, pemphigus, photosensitivity, sweating.
Vascular disorders: Flushing.
Potentially Fatal: Angioedema (including laryngeal angioedema and tongue oedema); anaphylactic/anaphylactoid reactions; cholestatic jaundice that may progress to fulminant hepatic necrosis.
Chỉ số theo dõi
Monitor blood pressure, renal function (e.g. BUN, serum creatinine), and serum K level (particularly in patients concomitantly taking K-sparing diuretics, K supplements and/or K-containing salts) periodically. Assess for signs of angioedema. Periodically monitor CBC with differential in patients with collagen vascular disease and/or renal impairment.
Quá liều
Symptoms: Hypotension which may be associated with electrolyte disturbances and renal failure. Management: Supportive treatment. If ingestion is recent, consider administration of activated charcoal; gastric decontamination (e.g. vomiting, gastric lavage) may be considered in the early period after ingestion. Monitor blood pressure and clinical symptoms. Ensure adequate hydration. Infuse 0.9% NaCl to treat marked hypotension and consider vasopressors (e.g. catecholamines) if necessary. Consider dialysis in patients with severe renal impairment.
Tương tác
Increased risk of hyperkalaemia with K-sparing diuretics (e.g. spironolactone, triamterene, amiloride), K supplements and/or K-containing salt substitutes. May enhance the hypotensive effect with diuretics. May increase the risk of hypoglycaemia with antidiabetic agents (e.g. insulins, oral hypoglycaemic agents). Concomitant use of NSAIDs may result in deterioration of renal function, including acute renal failure, and reduced antihypertensive effect of benazepril. May increase the risk of angioedema with mammalian target of rapamycin (mTOR) inhibitors (e.g. sirolimus, everolimus, temsirolimus). Increased serum concentration and toxicity of lithium. May cause nitritoid reactions (e.g. facial flushing, nausea, vomiting, hypotension) with Na aurothiomalate.
Potentially Fatal: Increased risks of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) with aliskiren. May increase the risk of angioedema with neprilysin inhibitors (e.g. sacubitril).
Ảnh hưởng đến kết quả xét nghiệm
May result in false-negative aldosterone/renin ratio (ARR).
Tác dụng
Description: Benazepril, a prodrug of benazeprilat, is an ACE inhibitor. It competitively inhibits the conversion of angiotensin I to angiotensin II (a potent vasoconstrictor) through the angiotensin I-converting enzyme (ACE) activity, thereby reducing the levels of angiotensin II which leads to an increase in plasma renin activity and decreased aldosterone secretion.
Onset: 1-2 hours (peak effect).
Duration: Approx 24 hours.
Absorption: Rapidly absorbed. Time to peak plasma concentrations: Benazepril: 0.5-1 hour; benazeprilat: 1-2 hours (fasting state); 2-4 hours (nonfasting state).
Distribution: Crosses the placenta (benazepril); enters breast milk in small amounts (benazepril and benazeprilat). Volume of distribution: Approx 8.7 L. Plasma protein binding: Approx 97% (benazepril); approx 95% (benazeprilat).
Metabolism: Rapidly and extensively metabolised in the liver to benazeprilat (active metabolite) via enzymatic hydrolysis; both benazepril and benazeprilat undergo glucuronidation. Undergoes extensive first-pass metabolism.
Excretion: Mainly via urine (approx 37%; 20% as benazeprilat, 12% as other metabolites, trace amounts of benazepril); faeces (approx 11-12% as benazeprilat). Elimination half-life: Benazeprilat: 10-11 hours (effective); 22 hours (terminal).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5362124, Benazepril. Accessed June 27, 2022.

Bảo quản
Store between 15-30°C. Protect from moisture.
Phân loại MIMS
Thuốc ức chế men chuyển angiotensin/Thuốc ức chế trực tiếp renin
Phân loại ATC
C09AA07 - benazepril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Tài liệu tham khảo
Anon. Benazepril. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 03/06/2022.

Anon. Benazepril. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/06/2022.

Benazepril Hydrochloride Tablet, Film Coated (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. Accessed 03/06/2022.

Buckingham R (ed). Benazepril Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 03/06/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Benazepril từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Cibacen
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in